13 investors back Hyderabad pharma and life sciences in 2026. The city makes a third of the world's vaccines. Quadria, Endiya, and Multiples fund pharma here, mostly at growth stage.
Hyderabad is India's undisputed bulk drug capital. It makes about a third of the world's vaccines.
Genome Valley holds 200-plus life-sciences firms. Bharat Biotech and Dr. Reddy's anchor the city.
Most pharma capital here is growth PE, not seed VC. Big cheques chase CDMOs and formulations.
Cheques skew large, from US$10M up. Big funds want proven plants and revenue.
Export demand keeps the plants busy. US and EU buyers drive most of the revenue.
Pharma diligence is long and document-heavy. Ellty keeps every file ready in one data room.
| Type | Check size | Sector focus | Website | |
|---|---|---|---|---|
| Quadria Capital | Healthcare PE fund | US$50M-$150M | Pharma, CDMO, hospitals | quadriacapital.com |
| InvAscent | Life-sciences PE fund | US$10M-$30M | Pharma, devices, diagnostics | invascent.com |
| Somerset Indus Capital | Healthcare PE fund | US$5M-$25M | Healthcare delivery, diagnostics | somersetinduscap.com |
| HealthQuad | Healthcare / digital-health VC | US$5M-$20M | Diagnostics, digital health, e-pharmacy | healthquad.com |
| Endiya Partners | Early-stage life-sciences VC | US$0.5M-$5M | Healthtech, diagnostics, cell therapy | endiya.com |
| Lighthouse Funds | Healthcare growth-PE fund | US$25M-$75M | Pharma, healthcare, consumer | lhfunds.com |
| ChrysCapital | PE with pharma franchise | US$50M-$200M | Pharma, generics, healthcare | chryscapital.com |
| Eight Roads Ventures | Healthcare / life-sciences VC | US$5M-$40M | Healthtech, pharma value chain | eightroads.com |
| Multiples Asset Management | Growth PE with pharma | US$30M-$100M | Pharma, CDMO, oncology | multiplesequity.com |
| Kotak Alternate Asset | Healthcare PE + life-sci VC | US$3M-$190M | Life sciences, drug discovery | kotakalternateasset.com |
| 360 ONE Asset | Healthcare PE platform | US$20M-$80M | Specialty pharma, CDMO, biologics | 360.one |
| Morgan Stanley PE Asia | Global PE, India pharma | US$30M-$100M | CDMO, injectables, hospitals | morganstanley.com |
| Everstone Capital | Mid-market PE, pharma vertical | US$30M-$100M | API, formulations, CDMO | everstonecapital.com |
Keep your pharma dossier investor-ready
Pharma funds run long, technical diligence on your plants and filings. Ellty logs every view in your data room.
Start free 14-day trialWhat a pharma investor backs
A pharma investor backs plants, pipelines, and IP. Most write large growth cheques, not seed.
Hyderabad funds skew to CDMO and formulations. Telangana investors back the wider state too.
They run deep private equity style diligence. They study your plants, filings, and approvals.
They check your export approvals carefully. US FDA and EU clearances lift the deal.
Ellty gives each fund one trackable link to your room. You see who studied your dossier before the call.
1 Bio is one of India's most important steps toward democratizing access to biologics scale-up and accelerating the journey from discovery to clinical readiness.
13 Hyderabad pharma investors
1. Quadria Capital
Quadria is Asia's largest dedicated healthcare PE fund.
Recent Activity: Put US$100M into Hyderabad's Aragen Life Sciences in 2025
LinkedIn: Quadria Capital LinkedIn
Sector Focus: Pharma, CDMO, hospitals
Stage Focus: Growth, buyout
Check Size: US$50M-$150M
Location: Singapore (backs Hyderabad pharma)
Website: quadriacapital.com
2. InvAscent
InvAscent runs India's leading life-sciences PE platform.
Recent Activity: Backs 36+ pharma, device, and healthcare companies
Sector Focus: Pharma, devices, diagnostics
Stage Focus: Growth
Check Size: US$10M-$30M
Location: Mumbai (backs India pharma)
Website: invascent.com
3. Somerset Indus Capital
Somerset Indus backs affordable healthcare delivery.
Recent Activity: A healthcare PE fund raising its third fund
LinkedIn: Somerset Indus Capital LinkedIn
Sector Focus: Healthcare delivery, diagnostics
Stage Focus: Growth
Check Size: US$5M-$25M
Location: Mumbai (backs India healthcare)
Website: somersetinduscap.com
4. HealthQuad
HealthQuad is Quadria's healthcare and digital-health VC.
Recent Activity: Launched a US$300M third fund in 2025
Sector Focus: Diagnostics, digital health, e-pharmacy
Stage Focus: Early to growth
Check Size: US$5M-$20M
Location: New Delhi / Gurugram (backs India)
Website: healthquad.com
5. Endiya Partners
Endiya is Hyderabad's rare early life-sciences VC.
Recent Activity: Backed SigTuple and Eyestem from Hyderabad
LinkedIn: Endiya Partners LinkedIn
Sector Focus: Healthtech, diagnostics, cell therapy
Stage Focus: Seed, Series A
Check Size: US$0.5M-$5M
Location: Hyderabad
Website: endiya.com
6. Lighthouse Funds
Lighthouse is a mid-market healthcare and consumer PE fund.
Recent Activity: Closed a US$475M fourth fund for growth deals
Sector Focus: Pharma, healthcare, consumer
Stage Focus: Growth
Check Size: US$25M-$75M
Location: Mumbai (backs India pharma)
Website: lhfunds.com
Share one link with every pharma fund
Ellty shows when Quadria or Endiya opens your dossier. Follow up with each fund at the right time.
Start free 14-day trial7. ChrysCapital
ChrysCapital is one of India's most prolific pharma backers.
Recent Activity: Backed Mankind, Intas, and Eris Lifesciences
Sector Focus: Pharma, generics, healthcare
Stage Focus: Growth, buyout
Check Size: US$50M-$200M
Location: Mumbai (backs India pharma)
Website: chryscapital.com
8. Eight Roads Ventures
Eight Roads runs a dedicated healthcare and life-sciences fund.
Recent Activity: Runs a US$250M healthcare and life-sciences fund
Sector Focus: Healthtech, pharma value chain
Stage Focus: Series A to growth
Check Size: US$5M-$40M
Location: Bengaluru (backs India pharma)
Website: eightroads.com
9. Multiples Asset Management
Multiples backs specialty pharma and contract manufacturing.
Recent Activity: Backed Encube Ethicals and Natco Pharma
LinkedIn: Multiples LinkedIn
Sector Focus: Pharma, CDMO, oncology
Stage Focus: Growth
Check Size: US$30M-$100M
Location: Mumbai (backs India pharma)
Website: multiplesequity.com
10. Kotak Alternate Asset
Kotak runs both a healthcare PE and a life-sciences VC.
Recent Activity: Backed Avammune Therapeutics in early drug discovery
Sector Focus: Life sciences, drug discovery
Stage Focus: Seed to growth
Check Size: US$3M-$190M
Location: Mumbai (backs India life sciences)
Website: kotakalternateasset.com
11. 360 ONE Asset
360 ONE runs a dedicated healthcare opportunities fund.
Recent Activity: Took a stake in OneSource Specialty Pharma
Sector Focus: Specialty pharma, CDMO, biologics
Stage Focus: Growth
Check Size: US$20M-$80M
Location: Mumbai (backs India pharma)
Website: 360.one
12. Morgan Stanley PE Asia
Morgan Stanley's Asia PE backs Indian pharma and hospitals.
Recent Activity: Backed Maiva Pharma and Hyderabad's Omega Hospitals
Sector Focus: CDMO, injectables, hospitals
Stage Focus: Growth, buyout
Check Size: US$30M-$100M
Location: Singapore (backed Omega Hospitals)
Website: morganstanley.com
13. Everstone Capital
Everstone is a mid-market PE with a real pharma vertical.
Recent Activity: Backed Softgel Healthcare and Slayback Pharma
Sector Focus: API, formulations, CDMO
Stage Focus: Growth, control
Check Size: US$30M-$100M
Location: Singapore (backs India pharma)
Website: everstonecapital.com
Genome Valley anchors the scene
Genome Valley is Asia's largest life-sciences cluster. It holds 200-plus firms and 15,000 scientists.
Telangana opened a new 1 Bio hub there in 2025. The old Pharma City is now a Green Pharma City.
New biologics labs lift the whole cluster. They draw global partners and capital.
Shared lab space cuts early build costs. Young firms scale without huge capex.
Plant data and filings are highly sensitive. Lock them behind tight granular permissions.
Run a clean due diligence process from day one. Ellty controls who opens each file.
Big PE, not early-stage VC
Pharma money here is PE and M&A, not seed VC. Big funds buy control of proven plants.
India healthcare drew US$3.5B in Q3 2025 alone. M&A drove most of that deal value.
A control buyer wants clean books. Plant audits decide most of these deals.
Most deals are mergers and acquisitions, not rounds. Early biotech VC stays thin in India.
Strategic buyers pay up for clean assets. A tidy data room can lift your price.
Read our due diligence for private equity guide. Ellty logs who opened each file and when.
From lab to funded company
Endiya is one of few seeding early life sciences. It backed SigTuple and Eyestem from Hyderabad.
A lab result still needs a clear path to market. Each stage wants a bigger proof point than the last.
Grants can fund your first trials. Private money joins once data looks strong.
A pharma partner can de-risk your scale-up. One deal often unlocks the next round.
Investors run deep due diligence on your data. Plant approvals and IP get the hardest look.
Ellty tracks who opened each file and exactly when. You can follow up at the right moment every time.
How to pitch a Hyderabad pharma investor
Lead with plants, filings, and approvals.
- 1.Lead with your plants, filings, and approvals.Pharma funds back proven assets first, so open with the sites and dossiers you hold.
- 2.Show a clear regulatory and IP pathway.Approvals and patents drive the value, so map every filing and its timeline.
- 3.Prove your export markets and real demand.US and EU buyers lift the deal, so show the orders and clearances behind them.
- 4.Share one Ellty link to your whole data room.Skip scattered email attachments and track who opens which files in real time.
- 5.Follow up the same day a fund digs in.Ellty flags the moment they open your dossier, so you reach out while interest is high.
How Ellty helps you land a pharma investor in Hyderabad
You've shortlisted your Hyderabad pharma funds already. Set up a data room before the first call.
- 1.Upload your filings, plant data, and deck.Set access per fund or per partner.
- 2.Share one trackable link with each fund.Each fund gets its own tracked link.
- 3.Watch opens and follow up at the right time.Use Ellty analytics to time each nudge.
Hyderabad pharma investor questions
- Quadria and Multiples lead the growth deals. Endiya seeds early life-sciences teams.
- Growth PE cheques run US$10M to US$150M. Early biotech VC writes far less than that.
- It makes a third of the world's vaccines. Genome Valley anchors the whole city.
- Yes, but it stays thin and rare. Most capital is growth PE and M&A.
- It was scrapped in its first form. It is now a smaller Green Pharma City.
- Before your very first investor call. Track who opens your dossier and files.
